Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report
Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events. However, airway inflammation caused by immune-related adverse events has rarely been reported. A 54-year-old wom...
Saved in:
| Published in: | Respiratory medicine case reports Vol. 49; p. 102035 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
01-01-2024
Elsevier |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events. However, airway inflammation caused by immune-related adverse events has rarely been reported. A 54-year-old woman with endometrial cancer experienced asthma exacerbation, and increased blood eosinophil counts 3 months after pembrolizumab administration. Although asthma exacerbation improved, the resumption of pembrolizumab caused the recurrence of dry cough and hypereosinophilia. The discontinuation of pembrolizumab improved her symptoms. Serum interleukin-5 levels increased during pembrolizumab treatment but decreased upon discontinuation. The blockade of PD-1 and its ligand may exacerbate asthma through eosinophilic inflammation. |
|---|---|
| AbstractList | Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events. However, airway inflammation caused by immune-related adverse events has rarely been reported. A 54-year-old woman with endometrial cancer experienced asthma exacerbation, and increased blood eosinophil counts 3 months after pembrolizumab administration. Although asthma exacerbation improved, the resumption of pembrolizumab caused the recurrence of dry cough and hypereosinophilia. The discontinuation of pembrolizumab improved her symptoms. Serum interleukin-5 levels increased during pembrolizumab treatment but decreased upon discontinuation. The blockade of PD-1 and its ligand may exacerbate asthma through eosinophilic inflammation. |
| ArticleNumber | 102035 |
| Author | Okazaki, Ryota Kitatani, Shin Ishikawa, Hiroki Yamasaki, Akira Harada, Tomoya Morita, Masato Uetani, Naoki Inui, Genki Yamaguchi, Kosuke Funaki, Yoshihiro Takata, Miki |
| Author_xml | – sequence: 1 givenname: Tomoya orcidid: 0000-0002-6820-4814 surname: Harada fullname: Harada, Tomoya email: tomo.h.308@tottori-u.ac.jp organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 2 givenname: Naoki surname: Uetani fullname: Uetani, Naoki organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 3 givenname: Genki surname: Inui fullname: Inui, Genki organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 4 givenname: Hiroki surname: Ishikawa fullname: Ishikawa, Hiroki organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 5 givenname: Yoshihiro surname: Funaki fullname: Funaki, Yoshihiro organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 6 givenname: Miki surname: Takata fullname: Takata, Miki organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 7 givenname: Ryota surname: Okazaki fullname: Okazaki, Ryota organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 8 givenname: Kosuke surname: Yamaguchi fullname: Yamaguchi, Kosuke organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 9 givenname: Masato surname: Morita fullname: Morita, Masato organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan – sequence: 10 givenname: Shin surname: Kitatani fullname: Kitatani, Shin organization: Department of Respirology, Tottori Prefectural Kousei Hospital, Tottori, Japan – sequence: 11 givenname: Akira surname: Yamasaki fullname: Yamasaki, Akira organization: Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38712312$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1u1DAUhS1URMvQF2CB_AIZbOfPQUioqvipVAkWsLau7ZvGQ2JHjmdKWfHoeAhU7QZvfH19z2f5nOfkxAePhLzkbMsZb17vtnEycSuYqHJDsLJ-Qs6E4GXBWMtPHtSn5HxZdiyvVnasFs_IaSlbLkouzsivLzjpGEb3cz-BLpy3e4OWwpKGCSj-AINRQ3LB01uXBjrczRgxLM6HeXCjAwreUhzxACnrnE8YR9x_d76o84mit2HCFB2M1IDPtDf0IlcL0ohziOkFedrDuOD5331Dvn14__XyU3H9-ePV5cV1YSrZpYK3TYui7htpoRGdgFbLvmGcm6YB1uuyYUJW0EPVMextJZm0ujLYStkyBFNuyNXKtQF2ao5ugninAjj1pxHijYKYnBlR1Ux0NZddB6yrSq41amuzX7JuqgrBZta7lTXv9YTWoE8RxkfQxzfeDeomHBTnrGVdRm2IWAkmhmWJ2N-LOVPHfNVOHfNVx3zVmm8WvXr47L3kX5p54O06gNnIg8OoFuMwm25dRJPyT93_-L8BAVW7bQ |
| CitedBy_id | crossref_primary_10_1007_s40278_024_59655_8 |
| Cites_doi | 10.1080/2162402X.2020.1722022 10.1038/s41467-020-17813-1 10.1111/cea.13017 10.1016/j.jaci.2012.12.1567 10.1016/j.ejca.2017.05.017 10.1186/s12890-020-01375-5 10.1016/S2213-2600(15)00367-7 10.1053/j.seminoncol.2023.01.003 10.1002/eji.201444778 10.1038/mi.2009.112 10.1111/j.1398-9995.2010.02458.x 10.1038/s41572-020-0160-6 10.1136/bcr-2018-227814 10.1093/annonc/mdx455 10.1016/j.jtho.2018.09.002 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors 2024 Published by Elsevier Ltd. 2024 Published by Elsevier Ltd. 2024 |
| Copyright_xml | – notice: 2024 The Authors – notice: 2024 Published by Elsevier Ltd. – notice: 2024 Published by Elsevier Ltd. 2024 |
| DBID | 6I. AAFTH NPM AAYXX CITATION 5PM DOA |
| DOI | 10.1016/j.rmcr.2024.102035 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2213-0071 |
| ExternalDocumentID | oai_doaj_org_article_502951899a09431bbebdd12385644ead 10_1016_j_rmcr_2024_102035 38712312 S2213007124000583 |
| Genre | Case Reports |
| GroupedDBID | .1- .FO 0R~ 0SF 1B1 1P~ 1~5 457 4G. 53G 5VS 6I. 7-5 AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABMAC ACGFS ADBBV ADEZE ADRAZ ADVLN AEVXI AEXQZ AFCTW AFRHN AFTJW AGHFR AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BCNDV DIK EBS EJD EO9 EP2 EP3 FDB GROUPED_DOAJ HYE HZ~ IPNFZ IXB KQ8 M41 M48 M~E NCXOZ O-L O9- RIG ROL RPM SES SSZ XH2 Z5R AFJKZ NPM AAYXX CITATION 5PM |
| ID | FETCH-LOGICAL-c489t-1767e25f68da6292a7b8f6011c66a0fb360284afa490efd4808db4ce78870eac3 |
| IEDL.DBID | RPM |
| ISSN | 2213-0071 |
| IngestDate | Tue Oct 22 15:13:15 EDT 2024 Tue Sep 17 21:29:29 EDT 2024 Thu Sep 26 21:18:11 EDT 2024 Sat Nov 02 12:25:46 EDT 2024 Sat Aug 24 15:41:16 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Pembrolizumab Immune-related adverse events Immune checkpoint inhibitor Eosinophil Asthma |
| Language | English |
| License | This is an open access article under the CC BY license. 2024 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c489t-1767e25f68da6292a7b8f6011c66a0fb360284afa490efd4808db4ce78870eac3 |
| ORCID | 0000-0002-6820-4814 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11070912/ |
| PMID | 38712312 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_502951899a09431bbebdd12385644ead pubmedcentral_primary_oai_pubmedcentral_nih_gov_11070912 crossref_primary_10_1016_j_rmcr_2024_102035 pubmed_primary_38712312 elsevier_sciencedirect_doi_10_1016_j_rmcr_2024_102035 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Respiratory medicine case reports |
| PublicationTitleAlternate | Respir Med Case Rep |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Uemura, Fukumitsu, Maeno (bib2) 2021; 9 Ogawa, Miyata, Maehara (bib13) 2019; 14 Helou, Shafiei-Jahani, Lo (bib15) 2020; 11 Maeno, Fukuda, Oguri, Niimi (bib4) 2017; 28 Singh, Stock, Akbari (bib10) 2011; 66 Varricchi, Galdiero, Loffredo (bib17) 2017; 7 Hamada, Yoshimura, Oshinomi (bib3) 2022; 101 Donato, Krol (bib6) 2019; 12 Bratke, Fritz, Nokodian (bib12) 2017; 47 Price, Rigazio, Campbell (bib16) 2015; 3 Holsbeke, Backer, Vos (bib18) 2018; 12 Wiel, ten Hacken, Postma (bib19) 2013; 131 Ramos-Casals, Brahmer, Callahan (bib1) 2020; 6 Scanvion, Béné, Gautier (bib7) 2020; 9 Harada, Naoi, Yasuda (bib5) 2021; 21 Akbari, Stock, Singh, Dekruyff (bib9) 2010; 3 Bernard-Tessier, Jeanville, Champiat (bib8) 2017; 81 McAlees, Lajoie, Dienger (bib11) 2015; 45 Kawakami, Saito, Takahashi (bib14) 2022; 49 Harada (10.1016/j.rmcr.2024.102035_bib5) 2021; 21 Price (10.1016/j.rmcr.2024.102035_bib16) 2015; 3 Singh (10.1016/j.rmcr.2024.102035_bib10) 2011; 66 Helou (10.1016/j.rmcr.2024.102035_bib15) 2020; 11 Donato (10.1016/j.rmcr.2024.102035_bib6) 2019; 12 Bratke (10.1016/j.rmcr.2024.102035_bib12) 2017; 47 Uemura (10.1016/j.rmcr.2024.102035_bib2) 2021; 9 Holsbeke (10.1016/j.rmcr.2024.102035_bib18) 2018; 12 Akbari (10.1016/j.rmcr.2024.102035_bib9) 2010; 3 Kawakami (10.1016/j.rmcr.2024.102035_bib14) 2022; 49 Scanvion (10.1016/j.rmcr.2024.102035_bib7) 2020; 9 McAlees (10.1016/j.rmcr.2024.102035_bib11) 2015; 45 Wiel (10.1016/j.rmcr.2024.102035_bib19) 2013; 131 Ogawa (10.1016/j.rmcr.2024.102035_bib13) 2019; 14 Varricchi (10.1016/j.rmcr.2024.102035_bib17) 2017; 7 Hamada (10.1016/j.rmcr.2024.102035_bib3) 2022; 101 Ramos-Casals (10.1016/j.rmcr.2024.102035_bib1) 2020; 6 Maeno (10.1016/j.rmcr.2024.102035_bib4) 2017; 28 Bernard-Tessier (10.1016/j.rmcr.2024.102035_bib8) 2017; 81 |
| References_xml | – volume: 12 year: 2019 ident: bib6 article-title: Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition publication-title: BMJ Case Rep. contributor: fullname: Krol – volume: 3 start-page: 81 year: 2010 end-page: 91 ident: bib9 article-title: PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions publication-title: Mucosal Immunol. contributor: fullname: Dekruyff – volume: 49 start-page: 439 year: 2022 end-page: 455 ident: bib14 article-title: Airway disorders associated with immune checkpoint inhibitor therapy: two case reports and a systematic review publication-title: Semin. Oncol. contributor: fullname: Takahashi – volume: 11 start-page: 3998 year: 2020 ident: bib15 article-title: PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity publication-title: Nat. Commun. contributor: fullname: Lo – volume: 9 start-page: e0835 year: 2021 ident: bib2 article-title: Asthma caused by durvalumab after chemoradiotherapy in two patients with non-small cell lung cancer, Respirol publication-title: Case Rep. contributor: fullname: Maeno – volume: 21 start-page: 6 year: 2021 ident: bib5 article-title: Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report publication-title: BMC Pulm. Med. contributor: fullname: Yasuda – volume: 47 start-page: 1417 year: 2017 end-page: 1425 ident: bib12 article-title: Differential regulation of PD-1 and its ligands in allergic asthma publication-title: Clin. Exp. Allergy contributor: fullname: Nokodian – volume: 45 start-page: 1019 year: 2015 end-page: 1029 ident: bib11 article-title: Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma publication-title: Eur. J. Immunol. contributor: fullname: Dienger – volume: 28 start-page: 2891 year: 2017 ident: bib4 article-title: Nivolumab-induced asthma in a patient with non-small-cell lung cancer publication-title: Ann. Oncol. contributor: fullname: Niimi – volume: 7 year: 2017 ident: bib17 article-title: Eosinophils: the unsung heroes in cancer? publication-title: Oncoiimunology contributor: fullname: Loffredo – volume: 131 start-page: 646 year: 2013 end-page: 657 ident: bib19 article-title: Small-airway dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review publication-title: J. Allergy Clin. Immunol. contributor: fullname: Postma – volume: 12 year: 2018 ident: bib18 article-title: Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler publication-title: Ther. Adv. Respir. Dis. contributor: fullname: Vos – volume: 9 year: 2020 ident: bib7 article-title: Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database publication-title: OncoImmunology contributor: fullname: Gautier – volume: 3 start-page: 849 year: 2015 end-page: 858 ident: bib16 article-title: Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study publication-title: Lancet Respir. Med. contributor: fullname: Campbell – volume: 101 year: 2022 ident: bib3 article-title: A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: a case report publication-title: Med. (Baltim.). contributor: fullname: Oshinomi – volume: 66 start-page: 155 year: 2011 end-page: 162 ident: bib10 article-title: Role of PD-L1 and PD-L2 in allergic diseases and asthma publication-title: Allergy contributor: fullname: Akbari – volume: 14 start-page: e9 year: 2019 end-page: e10 ident: bib13 article-title: Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC publication-title: J. Thorac. Oncol. contributor: fullname: Maehara – volume: 81 start-page: 135 year: 2017 end-page: 137 ident: bib8 article-title: Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies publication-title: Eur. J. Cancer contributor: fullname: Champiat – volume: 6 start-page: 38 year: 2020 ident: bib1 article-title: Immune-related adverse events of checkpoint inhibitors publication-title: Nat. Rev. Dis. Primers. contributor: fullname: Callahan – volume: 9 year: 2020 ident: 10.1016/j.rmcr.2024.102035_bib7 article-title: Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database publication-title: OncoImmunology doi: 10.1080/2162402X.2020.1722022 contributor: fullname: Scanvion – volume: 11 start-page: 3998 year: 2020 ident: 10.1016/j.rmcr.2024.102035_bib15 article-title: PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity publication-title: Nat. Commun. doi: 10.1038/s41467-020-17813-1 contributor: fullname: Helou – volume: 47 start-page: 1417 year: 2017 ident: 10.1016/j.rmcr.2024.102035_bib12 article-title: Differential regulation of PD-1 and its ligands in allergic asthma publication-title: Clin. Exp. Allergy doi: 10.1111/cea.13017 contributor: fullname: Bratke – volume: 131 start-page: 646 year: 2013 ident: 10.1016/j.rmcr.2024.102035_bib19 article-title: Small-airway dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2012.12.1567 contributor: fullname: Wiel – volume: 81 start-page: 135 year: 2017 ident: 10.1016/j.rmcr.2024.102035_bib8 article-title: Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.05.017 contributor: fullname: Bernard-Tessier – volume: 101 year: 2022 ident: 10.1016/j.rmcr.2024.102035_bib3 article-title: A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: a case report publication-title: Med. (Baltim.). contributor: fullname: Hamada – volume: 21 start-page: 6 year: 2021 ident: 10.1016/j.rmcr.2024.102035_bib5 article-title: Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report publication-title: BMC Pulm. Med. doi: 10.1186/s12890-020-01375-5 contributor: fullname: Harada – volume: 9 start-page: e0835 year: 2021 ident: 10.1016/j.rmcr.2024.102035_bib2 article-title: Asthma caused by durvalumab after chemoradiotherapy in two patients with non-small cell lung cancer, Respirol publication-title: Case Rep. contributor: fullname: Uemura – volume: 3 start-page: 849 year: 2015 ident: 10.1016/j.rmcr.2024.102035_bib16 article-title: Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(15)00367-7 contributor: fullname: Price – volume: 12 year: 2018 ident: 10.1016/j.rmcr.2024.102035_bib18 article-title: Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler publication-title: Ther. Adv. Respir. Dis. contributor: fullname: Holsbeke – volume: 49 start-page: 439 year: 2022 ident: 10.1016/j.rmcr.2024.102035_bib14 article-title: Airway disorders associated with immune checkpoint inhibitor therapy: two case reports and a systematic review publication-title: Semin. Oncol. doi: 10.1053/j.seminoncol.2023.01.003 contributor: fullname: Kawakami – volume: 45 start-page: 1019 year: 2015 ident: 10.1016/j.rmcr.2024.102035_bib11 article-title: Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma publication-title: Eur. J. Immunol. doi: 10.1002/eji.201444778 contributor: fullname: McAlees – volume: 3 start-page: 81 year: 2010 ident: 10.1016/j.rmcr.2024.102035_bib9 article-title: PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions publication-title: Mucosal Immunol. doi: 10.1038/mi.2009.112 contributor: fullname: Akbari – volume: 66 start-page: 155 year: 2011 ident: 10.1016/j.rmcr.2024.102035_bib10 article-title: Role of PD-L1 and PD-L2 in allergic diseases and asthma publication-title: Allergy doi: 10.1111/j.1398-9995.2010.02458.x contributor: fullname: Singh – volume: 6 start-page: 38 year: 2020 ident: 10.1016/j.rmcr.2024.102035_bib1 article-title: Immune-related adverse events of checkpoint inhibitors publication-title: Nat. Rev. Dis. Primers. doi: 10.1038/s41572-020-0160-6 contributor: fullname: Ramos-Casals – volume: 12 year: 2019 ident: 10.1016/j.rmcr.2024.102035_bib6 article-title: Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition publication-title: BMJ Case Rep. doi: 10.1136/bcr-2018-227814 contributor: fullname: Donato – volume: 28 start-page: 2891 year: 2017 ident: 10.1016/j.rmcr.2024.102035_bib4 article-title: Nivolumab-induced asthma in a patient with non-small-cell lung cancer publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx455 contributor: fullname: Maeno – volume: 14 start-page: e9 year: 2019 ident: 10.1016/j.rmcr.2024.102035_bib13 article-title: Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2018.09.002 contributor: fullname: Ogawa – volume: 7 year: 2017 ident: 10.1016/j.rmcr.2024.102035_bib17 article-title: Eosinophils: the unsung heroes in cancer? publication-title: Oncoiimunology contributor: fullname: Varricchi |
| SSID | ssj0000789052 |
| Score | 2.3201709 |
| Snippet | Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause... |
| SourceID | doaj pubmedcentral crossref pubmed elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 102035 |
| SubjectTerms | Asthma Case Report Eosinophil Immune checkpoint inhibitor Immune-related adverse events Pembrolizumab |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYoB9RLxaOP5SUfuFURxnEchxtPcQEhQaXeIj-12zZZlN2VECd-OjN2dmGlil56cx6KnflG4xl7_A0hB2XIQ2kkRKrMikxoxjJlTchY6XIrRGF4iKUT7sqbn-r8AmlyFqW-MCcs0QMnwR0WjIMTAFGBxhy4I2O8cQ7MrSpgJgcxROvL1JtgKtpgPN9Z8P6UTEro6hqLBKBcIF0Bi_XdXmeiSNj_9wlpOVnyzexzuU4-9W4jPUnD3SArvt0ka9f9xvgWeb71jcECPE-zRpsMAm2AzFE9mQ4bTf2jtiC-CALFlVc6hPCz8-PJqB0_4JKKprp1FM-ag-_pKJJIdH_87PeozQq4or5148bHEh_UoqJ0x_QEWhNP067DZ_Lj8uL-7CrriytkVqhqisSQpedFkMppySuuS6MCRGdHVkrNgskleB5CBy0q5oMTiilnhPWYfcjAWudfyGo7bv03QqWWBTcV2NYAEHmnuGNBSAetkjlVDcj3uaDrh8ShUc-Ty37VCEuNsNQJlgE5RSwWbyL_dbwBWlH3WlH_SysGpJgjWfeuRHIR4FOjdzv_mtBedJ9DRAk-MB8QtaQHS-NbftKOhpGnG0NrcMf49v_4ox3yEceZVn92yeq0m_k98mHiZvtR9V8AvNgKQw priority: 102 providerName: Directory of Open Access Journals |
| Title | Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report |
| URI | https://dx.doi.org/10.1016/j.rmcr.2024.102035 https://www.ncbi.nlm.nih.gov/pubmed/38712312 https://pubmed.ncbi.nlm.nih.gov/PMC11070912 https://doaj.org/article/502951899a09431bbebdd12385644ead |
| Volume | 49 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYHhAXxJulUPnADaXrOo7jcCulFZeiioeEuER-soHGWWV3pYoTP50ZJyldCXHgEjlPW56J5xt7_A0hL8uQh9JI8FSZFZnQjGXKmpCx0uVWiMLwkFInfCzff1FvT5EmR057YVLQvjXNYbxsD2OzTLGVq9YupjixxcX5CfosYOf4YkZmAA5v-Ohp_MW9nQUfd8gMwVx9a5H8kwukKmApt9sfK5TI-v9ujHYDJW9YnrN75O4IGenx0LT75JaPD8jt83FR_CH5deFbg8l3fm5bbTJwskFcjur1Ztlq6q-0ha5LAqA460qX4Hr2vls3sVvhdIqmOjqK-8wBdzqKBBL9pd_-aGJWwBn10XWtT-k9qEUl6V_TYyitPR1WHB6Rz2enn07eZWNihcwKVW2QFLL0vAhSOS15xXVpVADP7MhKqVkwuQTUIXTQomI-OKGYckZYj5GHDEbq_DHZi130TwmVWhbcVDCuhkrk3inuWBDSQalkTlVz8mrq6Ho18GfUU2DZ9xrFUqNY6kEsc_IGZXH9JHJfpwtd_60eNaAuGAdYCH6ixqjII2O8cQ4MsCoA28GPMSfFJMl6hBEDPIBPNf-s_Mkg7evqc_AmAf_yOVE7erDTvt07oLKJo3tS0Wf__-o-uYOtG-Z7npO9Tb_1L8hs7bYHaebgIKk9HL8WH34DiT8L-g |
| link.rule.ids | 230,315,729,782,786,866,887,2108,27935,27936,53803,53805 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokYAL78fy9IEbStd1HMfhVkqrIrpVJYrELfKzG2iSVXZXQpz46cw4SelKiENvTpzEVmbsmbE_f0PI2zykITcSIlVmRSI0Y4myJiQsd6kVIjM8xNQJX_KTb-rjAdLkyPEsTATtW1PtNBf1TlPNI7ZyUdvpiBObns72MWYBO8enW-QmDFiWXonS4wyMpzszPpyR6eFcXW2R_pMLJCtgMbvbXzsU6fr_bY42oZJXbM_hvev2-j65O3ibdK-vf0Bu-OYhuTUb9tMfkd-nvjaYt-fXutYmgfgcJO2oXq7mtab-p7bw16PsKC7Y0jlErZ1vl1XTLnAlRlPdOIpH1MFldRS5J7oLv_5RNUkGV9Q3rq19zAxCLepX957uQWnpab9Z8Zh8PTw42z9KhpwMiRWqWCGfZO55FqRyWvKC69yoAEHdrpVSs2BSCQ6L0EGLgvnghGLKGWE9ghYZTPLpE7LdtI1_RqjUMuOmgCk5FCL1TnHHgpAOSjlzqpiQd6OEykVPvVGOmLTvJcqzRHmWvTwn5AMK8fJJpM2ON9ruvBzEUGaMg0cJIaZGQOWuMd44B7ZbZeAWwpiakGxUgXLwQHrPAj5V_bfxp72aXDafQiAKrjOfELWhQBv926wBvYn03qOePL_-q2_I7aOz2XF5_Onk8wtyB3vaLxu9JNurbu1fka2lW7-Oo-YPfUEftA |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZokSouvB_L0wduKF3XsROnt9J2BYJWKwESt8hPNtAkq-yuhDjx05lxktKVEAe4OYkTW5mxZz57_A0hL_OQhtxkgFSZFYnQjCXKmpCw3KVWCGl4iKkTPuTnn9XJKdLkHI5nYWLQvjXVfnNR7zfVIsZWLms7HePEpvOzY8QsYOf4dOnCdIdch0HL5BWkHmdhPOEp-XBOpg_p6mqLFKBcIGEBixneftuiSNn_Z5O0HS55xf7Mbv1Pz2-Tm4PXSY_6OnfINd_cJXtnw776PfJz7muD-Xt-bGptEsDpIHFH9Wq9qDX137WFvx9lSHHhli4AvXa-XVVNu8QVGU114ygeVQfX1VHkoOgu_OZb1SQSrqhvXFv7mCGEWtSz7pAeQWnlab9pcZ98mp1-PH6TDLkZEitUsUZeydxzGTLldMYLrnOjAoC7A5tlmgWTZuC4CB20KJgPTiimnBHWY_Aig8k-fUB2m7bxjwjNdCa5KWBqDoVIvVPcsSAyB6WcOVVMyKtRSuWyp-Aox9i0ryXKtESZlr1MJ-Q1CvKyJtJnxxtt96UcRFFKxsGzBKipMbDywBhvnAMbriS4hzC2JkSOalAOnkjvYcCnqr82_rBXlcvmUwCk4ELzCVFbSrTVv-0noDuR5nvUlcf__uoLsjc_mZXv356_e0JuYEf71aOnZHfdbfwzsrNym-dx4PwCayQiNA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pembrolizumab-induced+asthma+exacerbation+with+hypereosinophilia+and+elevated+interleukin-5+in+endometrial+cancer%3A+A+case+report&rft.jtitle=Respiratory+medicine+case+reports&rft.au=Harada%2C+Tomoya&rft.au=Uetani%2C+Naoki&rft.au=Inui%2C+Genki&rft.au=Ishikawa%2C+Hiroki&rft.date=2024-01-01&rft.pub=Elsevier+Ltd&rft.issn=2213-0071&rft.eissn=2213-0071&rft.volume=49&rft_id=info:doi/10.1016%2Fj.rmcr.2024.102035&rft.externalDocID=S2213007124000583 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-0071&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-0071&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-0071&client=summon |